Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 31Glioblastoma 28Breast Neoplasms 20Lung Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Oropharyngeal Neoplasms 14Squamous Cell Carcinoma of Head and Neck 11Sarcoma 10Glioma 10Esophageal Neoplasms 10Brain Neoplasms 10Urinary Bladder Neoplasms 9Astrocytoma 9Gliosarcoma 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 7Mouth Neoplasms 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Melanoma 6Head and Neck Neoplasms 6Carcinoma, Hepatocellular 6Carcinoma 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Pancreatic Neoplasms 5Neoplasms 5Laryngeal Neoplasms 5Carcinoma, Squamous Cell 5Burkitt Lymphoma 5

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Radiation × 1 year × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡